3M Partnership With Cummins Expected to Increase Production of Filters for Powered Air Purifying Respirators

April 14, 2020

3M announced they have established a partnership with Cummins to increase the production of high-efficiency particulate filters for use in 3M’s powered air-purifying respirators, or PAPRs.

3M notes the partnership has the potential to more than double the current production of filters for 3M’s PAPRs. The additional filters are needed as the company has ramped up the production of PAPRs to meet a surge in demand for personal protective equipment due to the COVID-19 outbreak.

The company’s powered air-purifying respirators (PAPRs) are an important piece of personal protective equipment for front-line healthcare workers. PAPRs use a battery-powered blower that sends filtered air into a hood or head top that covers the head or face, and can provide increased levels of respiratory protection, especially for critical healthcare situations such as aerosol-generating procedures. PAPRs may also be more comfortable to wear for those who need respiratory protection for long periods of time.

Guided by a 3M design, employees in Cummins’ facility in Neillsville, Wisconsin, will use existing equipment typically used for producing diesel engine filters to make the PAPR filters. After assembly and testing, the filters will be sent to 3M’s plant in Valley, Nebraska, where the company’s PAPRs are manufactured. Production of the filters at Cummins Neillsville location is expected to begin by the end of April.

“3M continues to work around the clock to get personal protective equipment, including PAPRs, to the heroic healthcare workers and first responders on the frontlines of the COVID-19 fight,” said Mike Roman, 3M chairman of the board and chief executive officer. “Our partnership with Cummins will help us produce more of this critical equipment in the coming months.”

“Cummins has been striving to find out ways to help during the COVID-19 crisis,” said Tom Linebarger, Chairman and Chief Executive Officer of Cummins. “Working with 3M, we discovered that our technologies and manufacturing expertise could be relevant as we partner in new ways to help protect healthcare professionals.”

Since the COVID-19 outbreak began, 3M has increased production of critical safety and healthcare products at its manufacturing facilities in the U.S. and around the world. Beginning in January, 3M ramped up production of N95 and other respirators and doubled its global output to 1.1 billion per year – including 35 million a month in the United States. 3M has already put into motion additional investments and actions that will enable it to double its capacity again to 2 billion globally within 12 months, with additional capacity to begin coming online in the next 60 to 90 days. In the United States, 3M expects to produce N95 respirators at a rate of 50 million per month in June, a 40 percent increase from current levels.

3M is also working with the Trump administration on a plan to import 166.5 million 3M respirators from its overseas manufacturing facilities, starting this month.

In March, 3M announced a separate partnership with Ford to increase the production of PAPRs. 3M continues to explore opportunities to further expand its capacity and get healthcare supplies to where they’re needed most as quickly as possible.

Source3M

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”